Pfizer Halts Development of Oral Obesity Treatment Following Liver Injury Reports
Pfizer has stopped developing its once-daily weight-loss pill, danuglipron, after a patient experienced potential liver injury during trials.
Subscribe to unlock this story
We really don't like cutting you off, but you've reached your monthly limit. At just $5/month, subscriptions are how we keep this project going. Start your free 7-day trial today!
Get StartedHave an account? Sign in
Overview
Pfizer has decided to cease the development of danuglipron, its oral obesity treatment, after a participant in clinical trials faced liver issues. Despite the setback, Pfizer aims to pursue other obesity treatment options and remains committed to developing innovative medications. The weight-loss drug market is highly competitive, with rivals like Eli Lilly and Novo Nordisk offering alternatives that have generated significant sales. The company’s decision reflects the ongoing challenges in bringing effective weight-loss medications to market in light of potential safety concerns.
Report issue
Read both sides in 5 minutes each day
Analysis
- Pfizer is halting the development of danuglipron, an oral obesity treatment, after a participant in a trial experienced potential liver injury, although similar issues have been seen with other drugs in this category.
- Despite this setback, Pfizer remains committed to exploring other obesity treatments, as the obesity drug market is seen as a lucrative opportunity for pharmaceutical companies.
- Leading treatments are injectable, and there's a strong demand for oral alternatives that are more user-friendly, especially given that many patients face challenges accessing current treatments due to cost or insurance issues.
Articles (3)
FAQ
No FAQs available for this story.
History
- This story does not have any previous versions.